Concepts (84)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 7 | 2022 | 488 | 1.250 |
Why?
|
| Antiretroviral Therapy, Highly Active | 3 | 2013 | 62 | 0.580 |
Why?
|
| Anti-Retroviral Agents | 2 | 2021 | 20 | 0.440 |
Why?
|
| Herpes Zoster | 1 | 2013 | 4 | 0.430 |
Why?
|
| Vitamin D Deficiency | 1 | 2013 | 11 | 0.420 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2013 | 13 | 0.420 |
Why?
|
| HIV Seropositivity | 1 | 2013 | 51 | 0.410 |
Why?
|
| Oseltamivir | 1 | 2011 | 1 | 0.390 |
Why?
|
| Inappropriate Prescribing | 1 | 2011 | 5 | 0.380 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2011 | 16 | 0.380 |
Why?
|
| Influenza, Human | 1 | 2011 | 43 | 0.370 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2013 | 185 | 0.370 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2012 | 81 | 0.370 |
Why?
|
| Health Services | 1 | 2011 | 8 | 0.360 |
Why?
|
| Antiviral Agents | 1 | 2011 | 71 | 0.360 |
Why?
|
| Fluconazole | 1 | 2010 | 9 | 0.350 |
Why?
|
| Mycoses | 1 | 2010 | 23 | 0.340 |
Why?
|
| Infant, Extremely Low Birth Weight | 1 | 2010 | 22 | 0.340 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2010 | 32 | 0.340 |
Why?
|
| Antifungal Agents | 1 | 2010 | 43 | 0.340 |
Why?
|
| Pandemics | 1 | 2011 | 260 | 0.320 |
Why?
|
| Anti-HIV Agents | 2 | 2022 | 71 | 0.270 |
Why?
|
| United States | 4 | 2013 | 2201 | 0.250 |
Why?
|
| Female | 11 | 2022 | 15730 | 0.240 |
Why?
|
| Electronic Health Records | 2 | 2022 | 75 | 0.200 |
Why?
|
| Pre-Exposure Prophylaxis | 1 | 2022 | 5 | 0.200 |
Why?
|
| Risk Factors | 4 | 2012 | 2408 | 0.190 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2021 | 3 | 0.180 |
Why?
|
| Adult | 6 | 2021 | 8107 | 0.180 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2021 | 94 | 0.170 |
Why?
|
| Humans | 11 | 2022 | 28436 | 0.170 |
Why?
|
| Male | 8 | 2021 | 15291 | 0.170 |
Why?
|
| Middle Aged | 6 | 2021 | 9269 | 0.160 |
Why?
|
| HIV-1 | 1 | 2021 | 236 | 0.150 |
Why?
|
| Mass Screening | 1 | 2019 | 183 | 0.150 |
Why?
|
| Infant, Newborn | 2 | 2021 | 654 | 0.110 |
Why?
|
| Herpes Zoster Vaccine | 1 | 2013 | 2 | 0.110 |
Why?
|
| Herpesvirus 3, Human | 1 | 2013 | 4 | 0.110 |
Why?
|
| Chicago | 2 | 2019 | 946 | 0.110 |
Why?
|
| Health Care Surveys | 1 | 2013 | 66 | 0.110 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2013 | 54 | 0.100 |
Why?
|
| RNA, Viral | 1 | 2013 | 45 | 0.100 |
Why?
|
| Viral Load | 1 | 2013 | 73 | 0.100 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2012 | 14 | 0.100 |
Why?
|
| Attitude of Health Personnel | 1 | 2013 | 159 | 0.100 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 128 | 0.090 |
Why?
|
| Women's Health | 1 | 2013 | 176 | 0.090 |
Why?
|
| Pregnancy | 1 | 2012 | 342 | 0.090 |
Why?
|
| Odds Ratio | 1 | 2011 | 268 | 0.090 |
Why?
|
| HIV | 1 | 2011 | 43 | 0.090 |
Why?
|
| Sex Factors | 1 | 2012 | 476 | 0.090 |
Why?
|
| Incidence | 1 | 2013 | 773 | 0.090 |
Why?
|
| Adolescent | 2 | 2019 | 2307 | 0.090 |
Why?
|
| Cholestasis | 1 | 2010 | 10 | 0.090 |
Why?
|
| Disease Progression | 1 | 2013 | 717 | 0.090 |
Why?
|
| Candidiasis | 1 | 2010 | 22 | 0.090 |
Why?
|
| Minority Groups | 1 | 2011 | 86 | 0.090 |
Why?
|
| Predictive Value of Tests | 1 | 2011 | 492 | 0.090 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 517 | 0.080 |
Why?
|
| Infant, Premature, Diseases | 1 | 2010 | 31 | 0.080 |
Why?
|
| Socioeconomic Factors | 1 | 2011 | 309 | 0.080 |
Why?
|
| Cross-Sectional Studies | 1 | 2013 | 933 | 0.080 |
Why?
|
| Infant, Premature | 1 | 2010 | 219 | 0.080 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2010 | 210 | 0.070 |
Why?
|
| Prospective Studies | 1 | 2013 | 1809 | 0.070 |
Why?
|
| Child | 1 | 2011 | 1420 | 0.070 |
Why?
|
| Cyclohexanes | 1 | 2021 | 3 | 0.050 |
Why?
|
| Infusions, Intravenous | 1 | 2021 | 53 | 0.050 |
Why?
|
| Treatment Outcome | 1 | 2010 | 3615 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2021 | 163 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2021 | 147 | 0.040 |
Why?
|
| Respiration, Artificial | 1 | 2021 | 114 | 0.040 |
Why?
|
| HIV Antigens | 1 | 2019 | 11 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2021 | 433 | 0.040 |
Why?
|
| HIV Antibodies | 1 | 2019 | 16 | 0.040 |
Why?
|
| Program Development | 1 | 2019 | 64 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2019 | 137 | 0.040 |
Why?
|
| Urban Population | 1 | 2019 | 156 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2021 | 306 | 0.040 |
Why?
|
| Hospitalization | 1 | 2021 | 323 | 0.040 |
Why?
|
| Emergency Service, Hospital | 1 | 2019 | 259 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2021 | 1926 | 0.030 |
Why?
|
| Aged | 2 | 2021 | 9277 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2010 | 4857 | 0.010 |
Why?
|